-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UFZb2ng7+Da3zWCKFj0AoN6+i5HXb7V5niO8Lc5Vjlu0WV6XAmxhNID+cUdk13gk Vr1cO+iys+4Pel/o/li5sw== 0000921530-03-000288.txt : 20030501 0000921530-03-000288.hdr.sgml : 20030501 20030501171532 ACCESSION NUMBER: 0000921530-03-000288 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICIS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000859368 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521574808 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-97207 FILM NUMBER: 03677617 BUSINESS ADDRESS: STREET 1: 8125 NORTH HAYDEN ROAD CITY: SCOTTSDALE STATE: AZ ZIP: 85258 BUSINESS PHONE: 2125992000 MAIL ADDRESS: STREET 1: 8125 NORTH HAYDEN ROAD CITY: SCOTTSDALE STATE: AZ ZIP: 85258 424B3 1 supplement_no3.txt Filed Pursuant to Rule 424(b)(3) Registration No. 333-97207 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated November 22, 2002 Medicis Pharmaceutical Corporation 2.5% Contingent Convertible Senior Notes Due 2032 and Class A Common Stock Issuable Upon Conversion of the Notes This document supplements our prospectus dated November 22, 2002 (the "prospectus") relating to $400,000,000 aggregate principal amount of our 2.5% Contingent Convertible Senior Notes Due 2032 and the Class A common stock issuable upon conversion of the Notes. You should read this prospectus supplement in conjunction with the accompanying prospectus, which is to be delivered by selling securityholders to prospective purchasers along with this prospectus supplement and any other prospectus supplements. The information in the following table supplements the information under the caption "Selling Securityholders" in the prospectus.
Class A ----------------- ------------------- Common Stock Aggregate Principal Percentage of Beneficially Class A Common Amount of Notes that Notes Owned Prior to Stock Registered Name may be sold Outstanding Conversion(1) Hereby Akela Capital Master Fund, Ltd. $ 2,500,000 * * 43,029 ADI Alternative Investments c/o Kallista 3,000,000 * * 51,635 Master Fund B-Top Growth 3,000,000 * * 51,635 Convertible Securities Fund 100,000 * * 1,721 Kallister High Yield Master Fund Ltd. 1,000,000 * * 17,211 KBC Financial Products [Cayman Islands] 2,000,000 * * 34,423 Limited Nations Convertible Securities Fund 8,000,000 2.00 * 137,693 Privelege Portfolio Sicav 2,000,000 * * 34,423 Sage Capital 4,500,000 1.12 * 77,452 Subtotal $26,100,000 6.52 * 449,222
- ----------------- - -------------------------------------------------------------------------------- (1) Assumes that any other holders of Notes or any future transferee from any holder does not beneficially own any Class A common stock other than Class A common stock into which the Notes are convertible at the conversion price of 17.2117 shares per $1,000 principal amount of the Notes. Investing in the Notes and the Class A common stock issuable upon their conversion involves certain risks. See "Risk Factors" beginning on page 7 of the accompanying prospectus. Neither the securities and exchange commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus any representation to the contrary is a criminal offense. The date of this prospectus supplement is May 1, 2003. -----END PRIVACY-ENHANCED MESSAGE-----